Comorbidities in Children with COVID-19 and MIS-C/PIMS-TS and
                    Risk Factors for Hospitalization, Severe Disease, Intensive Care and
                    Death

Ankermann, Tobias; Brinkmann, Folke

doi:10.1055/a-1727-5895

Cited by 3 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to previous studies on adult lung transplant recipients, which show a high rate of hospitalization and death 9 , 10 , 11 , 12 , 13 , 14 , we did not observe any severe disease or deaths related to SARS-CoV-2 infection. Furthermore, no long-term effects or graft related complications occurred within the observation period, although preexisting comorbidities and immunosuppressive regimens in our cohort are comparable to previously described adult lung transplant populations 4 , 5 . This observation supports previous findings that age is one of the main risk factors for severe COVID-19 1,2 .…”

Section: Discussionsupporting

confidence: 79%

COVID-19 in pediatric lung transplant recipients: Clinical course and outcome

Schütz

Davids

Petrik

et al. 2023

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 79%

COVID-19 in pediatric lung transplant recipients: Clinical course and outcome

Schütz

Davids

Petrik

et al. 2023

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…Both of them had MIS-C. The current data about the severity of SARS-COV-2-induced disease suggests that the clinical course is much milder in children than in adults, the data that we gathered are also suggestive of [11][12][13][14][15][16].…”

Section: Cbcmentioning

confidence: 53%

COVID-19 in Hospitalized Children: A Single-Center Retrospective Study of 604 patients

2022

J Med Case Rep Case Ser

View full text Add to dashboard Cite

This study will contain a retrospective review of medical records for 604 pediatric patients with ages 0-18 years, who had a laboratoryconfirmed diagnosis of COVID-19 and were hospitalized between November 2020 and March 2021. The study was conducted following the Helsinki Declaration, 1975, and Tbilisi State Medical University (TSMU) ethics committee approval (approval by meeting record 9, 13.01.2022). The data was gathered at Children's New Clinic after Irakli Tsitsishvili. Classification of SeverityThe severity of the disease was classified into two groups: severe and non-severe [9]. Patients who were considered severe had either one or multiple of these conditions: dyspnea with desaturation (O2 < 92 %), acute respiratory distress (ARD), shock, encephalopathy, acute kidney injury (AKI), problems with coagulation, symptomatic myocardial involvement [10]. All the patients who didn't develop these conditions were considered non-severe.

show abstract

“…According to the results of this comprehensive analysis, children and adolescents had higher odds of hospitalisation and ICU admission if they had specific demographic characteristics and concomitant conditions. Corroborating studies also highlight that the odds of a severe COVID-19 outcome are substantially elevated for children with underlying risk factors compared with healthy children(55), underscoring that two or more comorbidities rather than single entities pose a risk for more severe courses of SARS-CoV-2 infection in children (55, 56).…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors for mortality, ICU, MIS-C and hospital admission due to SARS-CoV-2 in paediatric patients: A systematic review and meta-analysis

Vardavas,

Nikitara,

Mathioudakis

et al. 2024

Preprint

View full text Add to dashboard Cite

BackgroundThere is a paucity of data on the factors associated with severe COVID-19 disease, especially in children. This systematic review and meta-analysis aim to identify the risk factors for acute adverse outcomes of COVID-19 within paediatric populations, using the recruitment setting as a proxy of initial disease severity.MethodsA systematic review and meta-analysis were performed representing published evidence from the start of the pandemic up to 14 February 2022. Our primary outcome was the identification of risk factors for adverse outcomes, stratified by recruitment setting (community, hospital). No geographical restrictions were imposed. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to evaluate the certainty in the body of evidence for each meta-analysis. In anticipation of significant clinical and methodological heterogeneity in the meta-analyses, we fitted logistic regression models with random effects.FindingsOur review identified 47 studies involving 94,210 paediatric cases of COVID-19. Infants up to 3 months were more likely to be hospitalised than older children. Gender and ethnicity were not associated with an increased likelihood of adverse outcomes among children within the community setting. Concerning comorbidities, having at least one pre-existing disease increased the odds of hospitalisation. Concerning BMI, underweight children and severely obese were noted to have an increased likelihood of hospital admission. The presence of metabolic disorders and children with underlying cardiovascular diseases, respiratory disorders, neuromuscular disorders and neurologic conditions were also more likely to be hospitalised. Concerning underlying comorbidities, paediatric hospitalised patients with congenital/genetic disease, those obese, with malignancy, cardiovascular diseases and respiratory disease were associated with higher odds of being admitted to ICU or ventilated.InterpretationOur findings suggest that age, male, gender, and paediatric comorbidities increased the likelihood of hospital and ICU admission. Obesity, malignancy, and respiratory and cardiovascular disorders were among the most important risk factors for hospital and ICU admission among children with COVID-19. The extent to which these factors were linked to actual severity or where the application of cautious preventive care is an area in which further research is needed.

show abstract

Comorbidities in Children with COVID-19 and MIS-C/PIMS-TS and Risk Factors for Hospitalization, Severe Disease, Intensive Care and Death

Cited by 3 publications

References 34 publications

COVID-19 in pediatric lung transplant recipients: Clinical course and outcome

COVID-19 in pediatric lung transplant recipients: Clinical course and outcome

COVID-19 in Hospitalized Children: A Single-Center Retrospective Study of 604 patients

Prognostic factors for mortality, ICU, MIS-C and hospital admission due to SARS-CoV-2 in paediatric patients: A systematic review and meta-analysis

Contact Info

Product

Resources

About